Compare THCH & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THCH | VOR |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 1.1B |
| IPO Year | 2021 | 2021 |
| Metric | THCH | VOR |
|---|---|---|
| Price | $1.15 | $19.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $39.00 |
| AVG Volume (30 Days) | 14.9K | ★ 651.4K |
| Earning Date | 11-23-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $6.50 |
| 52 Week High | $2.70 | $26.00 |
| Indicator | THCH | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 48.14 | 51.86 |
| Support Level | $1.07 | $17.62 |
| Resistance Level | $1.57 | $20.11 |
| Average True Range (ATR) | 0.14 | 1.21 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 28.43 | 48.60 |
TH International Ltd is the exclusive master franchisee in China for Tim Hortons, a world-wide coffee and bakery shop brand. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under a single reportable segment, Tim Hortons. The company's revenue is derived from sales of food, beverages, and packaged products by company-owned and operated stores, franchise fees, and revenue from other franchise support activities. Its geographic revenue is derived from operations in the PRC.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.